Zobrazeno 1 - 10
of 97
pro vyhledávání: '"William A LaFramboise"'
Autor:
Cynthia Sears, Patrick Wagner, William A LaFramboise, Jianwu Xie, Neda Dadgar, Devin C Flaherty, Louis Gil Acevedo, Kunhong Kevin Xiao, Curtis Tilves, Justine Debelius, Ni Zhao, Noel Mueller
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/87a1bbec024949f3bbdf05f9205aa6f4
Autor:
Lisa H Butterfield, Howard Streicher, Patrick Hwu, Walter J Storkus, Ahmad A Tarhini, John M Kirkwood, F Stephen Hodi, Dung-Tsa Chen, Sandra J Lee, Issam El Naqa, William A LaFramboise, Arivarasan D Karunamurthy, Timothy I Shaw, Alyssa Obermayer
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/9d9afee52052458b9a1ac1d2f3366170
Autor:
Lisa H Butterfield, Howard Streicher, Patrick Hwu, Walter J Storkus, Ahmad A Tarhini, John M Kirkwood, F Stephen Hodi, Vernon K Sondak, Jose R Conejo-Garcia, Sandra J Lee, Aik-Choon Tan, Issam M El Naqa, William A LaFramboise, Arivarasan D Karunamurthy
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 1 (2022)
Externí odkaz:
https://doaj.org/article/32a3715be491424abf49ab6f4cedd4e3
Autor:
Albert Geskin, Elizabeth Legowski, Anish Chakka, Uma R Chandran, M Michael Barmada, William A LaFramboise, Jeremy Berg, Rebecca S Jacobson
Publikováno v:
PLoS ONE, Vol 10, Iss 6, p e0131166 (2015)
Next Generation Sequencing (NGS) methods are driving profound changes in biomedical research, with a growing impact on patient care. Many academic medical centers are evaluating potential models to prepare for the rapid increase in NGS information ne
Externí odkaz:
https://doaj.org/article/5c1a3bfa87684022aecab460fa3c1926
Autor:
Jon M Davison, Melissa Yee, J Michael Krill-Burger, Maureen A Lyons-Weiler, Lori A Kelly, Christin M Sciulli, Katie S Nason, James D Luketich, George K Michalopoulos, William A LaFramboise
Publikováno v:
PLoS ONE, Vol 9, Iss 1, p e79079 (2014)
Prognostic biomarkers are needed for superficial gastroesophageal adenocarcinoma (EAC) to predict clinical outcomes and select therapy. Although recurrent mutations have been characterized in EAC, little is known about their clinical and prognostic s
Externí odkaz:
https://doaj.org/article/c73657a7d58547b38117d60db8402258
Autor:
Rodolfo D Vicetti Miguel, Stephen A K Harvey, William A LaFramboise, Seth D Reighard, Dean B Matthews, Thomas L Cherpes
Publikováno v:
PLoS ONE, Vol 8, Iss 3, p e58565 (2013)
While Chlamydia trachomatis infections are frequently asymptomatic, mechanisms that regulate host response to this intracellular Gram-negative bacterium remain undefined. This investigation thus used peripheral blood mononuclear cells and endometrial
Externí odkaz:
https://doaj.org/article/ab5ed74610e74b28a569f8064de58d85
Autor:
Iyad Kobeissi, Islam Eljilany, Tala Achkar, William A. LaFramboise, Lucas Santana-Santos, Ahmad A. Tarhini
Publikováno v:
International Journal of Molecular Sciences; Volume 24; Issue 9; Pages: 8167
Despite the unprecedented advances in the treatment of melanoma with immunotherapy, there continues to be a major need for biomarkers of clinical benefits and immune resistance associated with immune checkpoint inhibitors; microRNA could play a vital
Autor:
Mariam Saad, Sandra J. Lee, Aik Choon Tan, Issam M. El Naqa, F. Stephen Hodi, Lisa H. Butterfield, William A. LaFramboise, Walter Storkus, Arivarasan D. Karunamurthy, Jose Conejo-Garcia, Patrick Hwu, Howard Streicher, Vernon K. Sondak, John M. Kirkwood, Ahmad A. Tarhini
Publikováno v:
Journal of translational medicine, vol 20, iss 1
Background We hypothesized that a gender difference in clinical response may exist to adjuvant CTLA4 blockade with ipilimumab versus high-dose IFNα (HDI). We investigated differences in candidate immune biomarkers in the circulation and tumor microe
Autor:
Alyssa N. Obermayer, Timothy I. Shaw, Sandra J. Lee, F. Stephen Hodi, William A. LaFramboise, Walter Storkus, Arivarasan D. Karunamurthy, Patrick Hwu, Howard Streicher, Dung-Tsa Chen, John M. Kirkwood, Ahmad A. Tarhini
Publikováno v:
Cancer Research. 83:5704-5704
Introduction CTLA4 blockade with ipilimumab was more favorable than interferon-α2b (IFN) in high-risk melanoma in phase adjuvant III trial E1609. Characterization of the pretreatment tumor immune biomarkers and clinical covariates may inform the lik
Autor:
Ahmad A Tarhini, Sandra J Lee, Aik-Choon Tan, Issam M El Naqa, F Stephen Hodi, Lisa H Butterfield, William A LaFramboise, Walter J Storkus, Arivarasan D Karunamurthy, Jose R Conejo-Garcia, Patrick Hwu, Howard Streicher, Vernon K Sondak, John M Kirkwood
Publikováno v:
Journal for immunotherapy of cancer, vol 10, iss 1
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 1 (2022)
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 1 (2022)
BackgroundMelanoma of unknown primary (MUP) represents a poorly understood group of patients both clinically and immunologically. We investigated differences in prognosis and candidate immune biomarkers in patients with unknown compared with those wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f6594a7e70e14c1deed6cba96d4698ce
https://escholarship.org/uc/item/4dh8b1ng
https://escholarship.org/uc/item/4dh8b1ng